---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-079871"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-07-01T20:15:26+00:00"
generated_at: "2026-07-01T20:17:24.201603+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cumberland closes $100M sale of branded products to Apotex; retains ifetroban pipeline

## Summary
- Sold Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ for $100M cash.
- Over 99% of shareholder votes supported the transaction.
- Company retains ifetroban candidates for Duchenne, systemic sclerosis, IPF, cancer metastasis.
- Terminated $5.3M Pinnacle Bank credit facility; repaid in full.
- Pro forma shows ~$110M cash, no product revenue, net loss from continuing ops.

## SEC filing metadata
- accession: 0001104659-26-079871
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-07-01T20:15:26+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/tm2619330d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-079871
- JSON: https://secwatch.observer/filing/0001104659-26-079871.json
- Plain text: https://secwatch.observer/filing/0001104659-26-079871.txt

## Key facts
- Executive change
  James L. Herman departed as Vice President Trade & Distribution and Corporate Compliance Officer at CUMBERLAND PHARMACEUTICALS INC.
  - Action: resign
  - Role: Vice President Trade & Distribution and Corporate Compliance Officer
  source text: Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm
- Executive change
  Chris T. Bitterman departed as Vice President Sales & Marketing at CUMBERLAND PHARMACEUTICALS INC.
  - Action: resign
  - Role: Vice President Sales & Marketing
  source text: Effective July 31, 2026, in connection with the closing of the Transaction, Chris T. Bitterman, Vice President Sales & Marketing, and James L. Herman, Vice President Trade & Distribution and Corporate Compliance Officer, will resign from the Company and will be hired by an affiliate of Apotex.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/0001104659-26-079871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.